CD40 and psoriasis vulgaris: 341G2 (bleselumab) is an hIgG4 antagonistic anti-CD40 mAb in clinical trials for plaque psoriasis and kidney transplant rejection (Anil Kumar et al., 2018, Harland et al., 2017).